UCLA Armored CAR T Cells Deliver Local VEGF Blockade, Improve Outcomes in Solid-Tumor Mouse Models

Overview

• Researchers reported in Science Translational Medicine that the approach is preclinical and based on mouse studies.
• Across models, the engineered cells outperformed conventional CAR T therapy and CAR T combined with systemic anti‑VEGF, curbing tumor growth and extending survival.
• In glioma models, complete responses reached 63–88% with the armored cells versus 0–38% with standard treatment.
• The therapy prevented treatment‑induced abnormal blood vessels and hypoxia seen with conventional CAR T and boosted antitumor signals such as interferon‑gamma.
• The cells secrete a VEGF‑neutralizing single‑chain fragment developed with Academia Sinica, focusing activity inside tumors and pointing to the need for further safety and translational work before human testing.